Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01363297 (Clinical Trial / Inotuzumab ozogamycin / CMC-544)

Study Title
Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia (NCT01363297)

Trial Description
The Phase 1 portion of this study will assess the safety, tolerability and efficacy at increasing dose levels of inotuzumab ozogamicin (also known as CMC-544) in subjects with CD22-positive relapsed or refractory adult acute lymphocytic leukemia (ALL) in order to select the recommended phase 2 dose (RP2D) and schedule.

The Phase 2 portion of the study will evaluate the efficacy of inotuzumab ozogamicin as measured by hematologic remission rate (CR + CRi) in patients in second or later salvage status.

This trial is sponsored by UCB Pharma/ Pfitzer. [1]

Study Data

  • Condition: Leukemia
  • Interventions:
    • Drugs used in this trial
      • Inotuzumab Ozogamicin (CMC-544)
  • Phase: II
  • Estimated Enrollment: 72
  • Start: August 2011
  • Estimated Completion: February 2016
  • Last verified: May 2015

Study Schematic 

NCT01363297 (Clinical Trial / Inotuzumab ozogamycin / CMC-544)

Click here to Return to Drug map


Last Editorial review: July 31, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar